We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Infectious Diseases

Infectious Diseases

Ask MedXY AI
What is the latest evidence?Key clinical updatesGuideline changes

Latest news

Evaluating Cardiovascular-Focused Messaging to Enhance Influenza Vaccination Uptake in Diverse U.S. Populations
Cardiologycardiovascular diseaseinfluenza vaccination

Evaluating Cardiovascular-Focused Messaging to Enhance Influenza Vaccination Uptake in Diverse U.S. Populations

By MedXY|Oct 3, 2025

A large randomized trial in the U.S. found no significant improvement in influenza vaccination rates with cardiovascular-focused messaging compared to usual care, despite prior positive findings in Denmark.

Revisiting Rehydration Strategies in Severe Acute Malnutrition with Gastroenteritis: Intravenous Versus Oral Approaches
Gastroenterologygastroenteritis

Revisiting Rehydration Strategies in Severe Acute Malnutrition with Gastroenteritis: Intravenous Versus Oral Approaches

By MedXY|Oct 6, 2025

A recent trial assessing intravenous versus oral rehydration in children with severe acute malnutrition and gastroenteritis found no mortality difference at 96 hours, challenging fears of fluid overload and supporting cautious consideration

Optimizing Empiric Antibiotic Selection in Hospitalized Patients with Skin and Abdominal Infections: Insights from the INSPIRE 3 and 4 Cluster Randomized Clinical Trials
General Surgery

Optimizing Empiric Antibiotic Selection in Hospitalized Patients with Skin and Abdominal Infections: Insights from the INSPIRE 3 and 4 Cluster Randomized Clinical Trials

By MedXY|Oct 6, 2025

The INSPIRE 3 and 4 trials demonstrate that computerized provider order entry (CPOE) prompts with patient-specific MDRO risk estimates, combined with education and feedback, significantly reduce empiric extended-spectrum antibiotic use in s

Clesrovimab: A Promising Monoclonal Antibody for Preventing RSV in Healthy Infants
Infectious Diseasesmonoclonal antibodyRSV

Clesrovimab: A Promising Monoclonal Antibody for Preventing RSV in Healthy Infants

By MedXY|Oct 9, 2025

A single dose of clesrovimab significantly reduces respiratory syncytial virus (RSV) infections and hospitalizations in healthy infants during their first RSV season, with a safety profile comparable to placebo.

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial
Clinical Updatesclinical trial

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

By MedXY|Oct 9, 2025

The endTB-Q trial assessed the efficacy and safety of a shortened BDLC regimen versus WHO standard care in rifampicin-resistant and fluoroquinolone-resistant tuberculosis, finding BDLC non-inferior in mITT but overall not non-inferior, high

Kissing Bugs and Chagas Disease: Understanding the Hidden Threat in the United States
Infectious DiseasesChagas diseaseKissing bug

Kissing Bugs and Chagas Disease: Understanding the Hidden Threat in the United States

By MedXY|Oct 8, 2025

Approximately 280,000 Americans are infected with Chagas disease, transmitted by kissing bugs. This article explores the ecology, health risks, detection, and prevention of this often-overlooked disease.

PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial
Clinical Updateshepatitis B

PegIFN Alpha-2a Therapy Reduces Relapse Risk after NUC Discontinuation in HBeAg-Negative Chronic Hepatitis B: Insights from a Randomized Controlled Trial

By MedXY|Oct 8, 2025

Switching from nucleo(s)tide analogues to pegylated interferon alpha-2a significantly lowers virological relapse and boosts HBsAg clearance in HBeAg-negative chronic hepatitis B patients after treatment cessation.

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial
Clinical Updatesantiviral therapybepirovirsen

Sequential Pegylated Interferon after Bepirovirsen Lowers Relapse Risk in Chronic Hepatitis B: Insights from the B-Together Trial

By MedXY|Oct 8, 2025

The B-Together phase IIb study demonstrates that sequential therapy with bepirovirsen followed by pegylated interferon-α-2a reduces post-treatment relapse in chronic hepatitis B patients on stable nucleos(t)ide analogue therapy, with enhanc

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial
Clinical Updatesdose optimizationPharmacokinetics

Optimizing Pyrazinamide Dosing in Drug-Susceptible Pulmonary Tuberculosis: Insights from a Large Phase 3 Trial

By MedXY|Oct 8, 2025

A comprehensive analysis from the TBTC Study 31/ACTG A5349 reveals that flat dosing of pyrazinamide at 1,000 mg daily optimizes efficacy and safety, challenging current weight-banded dosing strategies for drug-susceptible tuberculosis.

Optimizing Hepatitis C Screening in Emergency Departments: Insights from the DETECT Hep C Randomized Clinical Trial
Emergency Medicineemergency departmentHepatitis C

Optimizing Hepatitis C Screening in Emergency Departments: Insights from the DETECT Hep C Randomized Clinical Trial

By MedXY|Oct 7, 2025

The DETECT Hep C trial demonstrates nontargeted HCV screening in emergency departments identifies more new infections than risk-based approaches, though linkage to care remains suboptimal, underscoring the need for innovative treatment mode

Evaluating Germicidal UV Light to Reduce Respiratory Infections in Long-Term Care: Insights from a South Australian Randomized Trial
Clinical Updatesacute respiratory infectionsGermicidal UV light

Evaluating Germicidal UV Light to Reduce Respiratory Infections in Long-Term Care: Insights from a South Australian Randomized Trial

By MedXY|Oct 7, 2025

A randomized clinical trial in South Australian long-term care facilities found germicidal UV light appliances did not significantly reduce acute respiratory infection rates per cycle but modestly lowered total infections over time, suggest

One Dose or Three? Reevaluating Benzathine Penicillin G Therapy for Early Syphilis
Dermatology

One Dose or Three? Reevaluating Benzathine Penicillin G Therapy for Early Syphilis

By MedXY|Oct 6, 2025

A recent multicenter trial demonstrates that a single dose of benzathine penicillin G is noninferior to three doses in treating early syphilis, including patients with HIV, simplifying management and reducing adverse effects.

Decoding Immune Dynamics in HBV-Related Acute-on-Chronic Liver Failure: Insights from Single-Cell Multimodal Analysis
Clinical Updatesimmune dysregulationsingle-cell multiomics

Decoding Immune Dynamics in HBV-Related Acute-on-Chronic Liver Failure: Insights from Single-Cell Multimodal Analysis

By MedXY|Oct 6, 2025

This longitudinal single-cell multiomics study delineates the evolving immune landscape in HBV-ACLF, identifying key immune cell subsets and signaling pathways that drive disease progression and highlight potential therapeutic targets for p

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma
Clinical UpdatesHBVhepatocellular carcinoma

SCG101: A Novel HBV-Specific TCR-T Therapy Shows Promising Results in Advanced HBV-Related Hepatocellular Carcinoma

By MedXY|Oct 6, 2025

SCG101, an HBV-specific T-cell receptor T-cell therapy, demonstrates significant antiviral and antitumour efficacy with a manageable safety profile in patients with advanced HBV-related hepatocellular carcinoma refractory to prior treatment

Azelastine Nasal Spray Significantly Reduces SARS-CoV-2 Infection Risk: Results from a Phase 2 Randomized Clinical Trial
Infectious DiseasesSARS-CoV-2

Azelastine Nasal Spray Significantly Reduces SARS-CoV-2 Infection Risk: Results from a Phase 2 Randomized Clinical Trial

By MedXY|Oct 6, 2025

This phase 2 trial demonstrates that azelastine nasal spray reduces SARS-CoV-2 infections and symptomatic respiratory illnesses in a healthy, vaccinated adult population, suggesting its potential as a safe, scalable prophylactic measure aga

Evaluating RSV Vaccine Effectiveness Against Hospitalization in US Adults Aged 60 and Older Over Two Seasons
Clinical Updateshospitalizationolder adults

Evaluating RSV Vaccine Effectiveness Against Hospitalization in US Adults Aged 60 and Older Over Two Seasons

By MedXY|Oct 6, 2025

A large multicenter study demonstrates that a single dose of RSV vaccine reduces hospitalization risk by 58% among adults aged 60+, with lower effectiveness in immunocompromised and cardiovascular patients.

Is Piperacillin-Tazobactam Safe for Patients with Amoxicillin Allergy? Insights from a Recent Clinical Study
Clinical Updatespenicillin allergyPiperacillin-tazobactam

Is Piperacillin-Tazobactam Safe for Patients with Amoxicillin Allergy? Insights from a Recent Clinical Study

By MedXY|Oct 5, 2025

A recent study shows that over 80% of patients allergic to amoxicillin tolerate piperacillin-tazobactam, though about 18% experience cross-reactivity, highlighting the need for careful allergy testing before use.

Enhancing Early Risk Stratification of Severe Childhood Febrile Illness in Rural Asia Using sTREM1 Biomarker
Emergency Medicinerisk stratification

Enhancing Early Risk Stratification of Severe Childhood Febrile Illness in Rural Asia Using sTREM1 Biomarker

By MedXY|Oct 5, 2025

A multicountry study across Asia demonstrates soluble TREM1’s superior accuracy over traditional clinical signs in predicting severe febrile illness in children, potentially transforming triage in resource-limited settings.

Unraveling Mitochondrial Dysfunction as a Key Pathological Feature in Long COVID Syndrome
Infectious DiseasesBioenergeticslong COVID

Unraveling Mitochondrial Dysfunction as a Key Pathological Feature in Long COVID Syndrome

By MedXY|Oct 5, 2025

Long COVID patients exhibit distinct mitochondrial bioenergetic impairments, with altered ATP synthase function correlating with clinical symptoms and quality of life, implicating mitochondrial dysfunction in its pathogenesis.

Case Report: Unilateral Renal Agenesis Presenting as Recurrent Urinary Tract Infections in a 25-Year-Old Woman
Infectious Diseasescase reportdiagnosis

Case Report: Unilateral Renal Agenesis Presenting as Recurrent Urinary Tract Infections in a 25-Year-Old Woman

By MedXY|Oct 5, 2025

A 25-year-old woman with recurrent urinary tract infections was diagnosed with unilateral renal agenesis, highlighting the importance of imaging in persistent urinary symptoms.

Prev
14 / 16
1…1213141516
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities

Browse by specialty

Open language-specific specialty feeds and department pages.

news6629 articlesCardiology1375 articlesClinical Updates1288 articlesOncology1139 articlesDiabetes & Endocrinology842 articlesNeurology820 articlesPublic Health595 articlesGastroenterology572 articles
Hematology-Oncology
487 articles
Pediatrics484 articles
Internal Medicine444 articles